A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

NCT01476345 | Completed Phase 1 Results

• 2 other identifiers: 13711I4L-MC-ABEA
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy participants. Each study period will be approximately 8.5 days (1.5 days for treatment and 7 day washout period). There are 4 study periods.

Conditions

Diabetes Mellitus

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus

  1 hour predose up to 24 hours postdose in all treatment periods

• Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus

  1 hour predose up to 24 hours postdose in all treatment periods

Secondary Outcomes (2)

• Maximum Glucose Infusion Rate (Rmax)

  1 hour predose up to 24 hours postdose in all treatment periods

• Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure

  1 hour predose up to 24 hours postdose in all treatment periods

Study Arms (2)

LY2963016

EXPERIMENTAL

A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.

Drug: LY2963016

Lantus

EXPERIMENTAL

A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.

Drug: Lantus

Interventions

LY2963016 DRUG

Administered subcutaneously

LY2963016

Lantus DRUG

Administered subcutaneously

Lantus

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• are overtly healthy males or females, as determined by medical history and physical examination
• male participants: agree to use a reliable method of birth control during the study.
• female participants of child-bearing potential must test negative for pregnancy at the time of enrollment and agree to either abstain from sexual activity or to use a medically accepted means of contraception when engaging in sexual intercourse throughout the study, or female participants not of child-bearing potential due to surgical sterilization or menopause
• have a body weight of at least 55 kilograms (kg), and body mass index (BMI) of 18.5 to 32.0 kilograms/square meter (kg/m²)
• have clinical laboratory test results within normal reference range for the population
• have venous access sufficient to allow for blood sampling
• are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
• have given written informed consent
• participants should have a normal oral glucose tolerance test

You may not qualify if:

• are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product other than the investigational product used in this study; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• have known allergies to heparin, insulin glargine, related compounds or any components of the formulation
• are persons who have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY2963016
• have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
• have an abnormal blood pressure as determined by the investigator
• have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication
• show evidence of significant active neuropsychiatric disease
• regularly use known drugs of abuse and/or show positive findings on urinary drug screening
• show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
• show evidence of hepatitis C and/or positive hepatitis C antibody
• show evidence of hepatitis B and/or positive hepatitis B surface antigen
• are women with a positive pregnancy test or women who are lactating
• intend to use over-the-counter or prescription medication
• have donated blood of more than 500 milliliters (mL) within the last 56 days before dosing of Period 1
• have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption for 24 hours before dosing and throughout the duration of each study period

Sponsors & Collaborators

• Eli Lilly and Company: lead

Study Sites (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Bloemfontein, 9301, South Africa

Location

MeSH Terms

Conditions

Diabetes Mellitus

Interventions

LY2963016 insulin glargine; Insulin Glargine

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Insulin, Long-Acting; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Results Point of Contact

• Title: Chief Medical Officer
• Organization: Eli Lilly and Company

800-545-5979

Study Officials

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

  Eli Lilly and Company

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 5, 2011
• First Posted: November 22, 2011
• Study Start: November 1, 2011
• Primary Completion: July 1, 2012
• Study Completion: July 1, 2012
• Last Updated: October 7, 2014
• Results First Posted: October 7, 2014

Record last verified: 2014-10

Locations

ZA (1)